
Vera Therapeutics (VERA) Stock
Clinical biotech company developing immune and respiratory therapies. Here's the price, business snapshot, and what's worth knowing about Vera Therapeutics in November 2026.
Vera Therapeutics Inc (VERA) is a clinical-stage biotechnology company developing novel therapies targeting immune-mediated and respiratory conditions. With a market capitalisation of around US$1.94bn, it attracts attention from investors interested in innovation-driven small caps. The company’s value largely depends on pipeline progress, clinical trial results and regulatory milestones, so share price can be volatile. For long-term investors, key considerations include the strength of the balance sheet, upcoming data readouts, partner and licensing agreements, and competitive landscape. Vera may offer upside if trials succeed, but there is significant risk if development programmes encounter delays or negative results. This summary provides general, educational information — not personalised investment advice. Investors should review company filings, seek professional advice if needed and only invest money they can afford to risk, because biotech stocks can experience wide price swings and outcomes are uncertain.
Vera Therapeutics (VERA) Stock Forecast
Analyst price target, next 12 months
$67.30
+147.3% vs today's $27.22
Price range over the last 12 months
Close to its 12-month low
Analysts covering Vera Therapeutics have a consensus 12-month target of $67.30, above the current price of $27.22.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VERA Therapeutics' stock with a target price of $67.3, indicating significant potential for growth.
Financial Health
VERA Therapeutics is generating solid revenue and cash flow, with a strong profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
Why You’ll Want to Watch This Stock
Clinical-stage focus
Pipeline milestones and trial readouts are primary value drivers; successful data can boost prospects, though outcomes are uncertain and can move prices sharply.
Scientific innovation
Investment interest often centres on novel approaches and partnerships, but scientific promise does not guarantee commercial success.
Market dynamics
Competition, regulatory environment and financing needs shape the opportunity; consider diversification since biotech stocks can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.